In RA, Safety Similar for Anti-TNF vs. Triple Therapy
The rates of serious infections did not differ substantially among patients with rheumatoid arthritis treated with methotrexate plus a tumor necrosis factor (TNF) inhibitor and those receiving triple therapy, noted a real-world cohort study.There also were no significant differences between the groups on secondary outcomes, with a weighted hazard ratio of 1.41 (95% CI 0.85-2.34) for bacterial infection and 0.80 (95% CI 0.55-1.18) for herpes zoster, the researchers reported in Arthritis Care & Resear
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies